Phase 4 N=2 Efficacy and Safety of Omalizumab in Bullous Pemphigoid
Bullous Pemphigoid
Primary: Median Time From First Dose of Omalizumab Treatment to Cessation of New Blisters. — 6 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=106 A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Percent of Participants Achieving Sustained Remission at Week 36 — 4.0; 18.2 Estimated Percentage of Participants — p=0.0250
Phase 2 N=8 Rituximab in the Treatment of Patients With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Primary Safety Endpoint — 0; 0; 1 participants
Phase 2 N=4 Ixekizumab in the Treatment of Bullous Pemphigoid
Bullous Pemphigoid · Pemphigoid
Primary: Cessation of Blister Formation — NA days
Phase 2 N=11 Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Pemphigoid, Bullous
Primary: Number of Participants With Anti-Drug Antibodies — 0 Participants
Phase 3 N=98 A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Bullous Pemphigoid
Primary: Number of Participants With CRoff at Week 36 — 8; 2 Participants
Phase 2 N=3 Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Phase 2 N=27 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Pemphigus Vulgaris
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 74.1; 86.7; 11.1; 0 percentage of participants
Phase 2 N=20 Use of Infliximab for the Treatment of Pemphigus Vulgaris
Pemphigus
Primary: Participant Response to Treatment at Week 18 — 1; 1 Participants — p=1.00
Phase 2 N=23 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants
Phase 3 N=135 A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
Pemphigus Vulgaris
Primary: Percentage of Participants (Excluding Telemedicine [TM] Participants) Who Achieved Sustained Complete Remission, Evaluated by the Pemphigus Disease Area Index (PDAI)…
N/A N=20 Broad Band Light for the Treatment and Prevention of Senile Purpura
Senile Purpura · Bateman's Purpura
Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions
Phase 2 N=10 Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
Inherited Epidermolysis Bullosa
Primary: Intra-individual Difference in Reepithelialization of Wound (Halves) at Day 14 in 'Recent Wounds' or Day 28 in 'Chronic Wounds' — 8; 0 Wounds — p==0.008
Phase 2 N=8 Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Blister/Erosion Reduction Based on Change in Body Surface Area (BSA) Coverage — 57.25; 39.40; 27.25; 25.45 percentage of BSA involvement
Phase 3 N=223 Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment — 45; 33 Participants — p=0.013
Phase 2 N=4 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum
Pyoderma Gangrenosum
Primary: The Proportion of Subjects Achieving 2-point Reduction in the 5-point Investigator Global Assessment (IGA) for the Target Ulcer at Week 12 — 0 Participants — p=1
Phase 2 N=48 Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Participants With Documented Complete Closure Of The Target Wound Within 1 Month After Initiation Of Treatment — 8; 6; 7; 7 Participants — p==0.3699
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=61 Urticaria Facticia Treatment With Omalizumab (UFO)
Symptomatic Dermographism
Primary: Change in Provocation Thresholds From Baseline to Day 70 in Urticaria Factitia Patients After Treatment With Omalizumab Compared to Placebo — -1.8; -2.0; -0.6 wheal…
Phase 2 N=59 Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
Psoriasis
Primary: Percentage of Participants With Palmoplantar (pp) Pustular Psoriasis Area and Severity Index 50 (PASI) (ppPASI50) at Week 16 — 31.6; 31.6; 23.8 Percentage of…
N/A N=2 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease
Pyoderma Gangrenosum · Crohn's Disease · Ulcerative Colitis
Primary: The Efficacy of Infliximab in Pyoderma Gangrenosum in Adult Subjects Who Have Inflammatory Bowel Disease — 1 participants
Phase 3 N=222 A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
Pemphigus Vulgaris · Pemphigus Foliaceus
Primary: Number of Pemphigus Vulgaris (PV) Participants Who Achieve Complete Clinical Remission (CR) on Minimal Prednisone Therapy — 44; 20 Participants
Phase 2 N=14 Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Epidermolysis Bullosa · Pruritus
Primary: Comparative Weekly Change in NRS Itch Score Over the 8-week Active Treatment Period — -2; -1 score/week comparative change
Phase 3 N=94 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
Pemphigus Vulgaris (PV)
Primary: Percentage of Patients Achieving Responder Status at Week 52 — 63.9; 69.0 Percentage of Participants — p=0.6558
Phase 3 N=169 ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
Epidermolysis Bullosa
Primary: Time To Complete Target Wound Closure Within 3 Months — 41.6; 53.6 days — p=0.985
Phase 2 N=20 Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Phase 2 N=51 Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Epidermolysis Bullosa · Epidermolysis Bullosa Simplex
Primary: Treatment-emergent Adverse Events — 40 Participants
N/A N=10 Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Percentage of Wound Surface Area Change From Baseline to Week 8 — -63; -8.1 percentage of wound surface area
Phase 2 N=6 Apremilast for Erythema Multiforme
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
N/A N=39 Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers
Diabetic Foot Ulcers
Primary: Size of Index Wound Based on Calculations Wound Width x Length x Depth 2. Size of Index Wound Based on Calculations Wound Width x Length x Depth — 2.05; 3.33 mm^3